Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

TSMC forecasts jump in second-quarter sales

(Sharecast News) - Taiwan Semiconductor Manufacturing Co said on Thursday it expects sales to jump in the second quarter on strong demand. The world's largest chip maker said second-quarter sales were likely to come in between US$19.6bn and US$20.4bn, an increase of up to 30%.

The update came as TSMC, a major supplier to Apple, posted first-quarter numbers showing a near 17% year-on-year increase in net sales, to NT$592.6bn (US$18.3bn), in the three months to 31 March.

Net income jumped 9% to NT$225.5bn, ahead of expectations for around NT$218bn.

However, compared to the fourth quarter of 2023, revenues eased 5.3% and net income nearly 6%.

Wendell Huang, chief financial officer, said: "Our business in the first quarter was impacted by smartphone seasonality, partially offset by continued high performance computing-related demand.

"Moving into the second quarter, we expect our business to be supported by strong demand for our industry-leading 3mm and 5mm technologies, partially offset by continued smartphone seasonality."

Chief executive CC Wei said: "Almost all of the AI innovators are working with TSMC to address the insatiable AI-related demand for energy efficient computing power.

"AI-related data centre demand is very, very strong."

Joshua Mahony, chief market analyst at Scope Markets, said: "We have seen some grounds for optimism from the world's largest chip manufacturer.

"Recently viewed as a key barometer of AI chip demand, there is a hope that the likes of Nvidia and Arm Holdings will see the buyers step in once again on the hope that we will see a similarly upbeat tone when they report in the coming weeks."

Share this article

Related Sharecast Articles

AstraZeneca reports positive results from blood cancer drug trial
(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.
Standard Chartered posts jump in Q1 profits
(Sharecast News) - Standard Chartered backed its full-year guidance on Thursday and posted a jump in first-quarter profit as it continued to benefit from higher interest rates.
Revolution Bars confirms takeover talks with Nightcap
(Sharecast News) - Revolution Bars confirmed on Thursday that it has held "an exploratory meeting" with Piano Works owner Nightcap about a range of possible transactions, including a potential takeover.
Engine sales drive Q1 growth at Melrose
(Sharecast News) - Aerospace tech group Melrose reported a strong start to the year with its Engines division driving group revenues higher, as it reiterated recently upgraded guidance for the full year.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.